UNSPSC 51142518: Apomorphine or apomorphinum

This classification denotes a dopamine agonist and antiparkinsonian agent with the molecular formula C17H17NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N21FAR7B4S, chemically known as 6a.beta.-noraporphine-10,11-diol, 6-methyl-, hydrochloride but generally known as apomorphine, which bears US NIH Compound Identifier 2215. Apomorphine most often comes in base, chloride, diacetate, hydrochloride, and hydrochloride hemihydrate forms.

European Medicines Agency schedules Apomorphine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12923MIG. World Health Organization schedules apomorphine in its Anatomical Therapeutic Chemical (ATC) Classification. Apomorphine or apomorphinum bears US NLM identifiers UMLS ID C0003596 and NCI Concept Code C61639. SMILES: OC1C2C3C4C(N(CCC4CCC3)C)CC2CCC1O.

UNSPSC 51142518 Apomorphine or apomorphinum is a Commodity code that in recent state and local procurement does not appear to map to actual buying activity for apomorphine specifically. The three recent opportunities tagged under this code — Seminole County's procurement for naloxone and drug deactivation systems, Texas HHS's RFI on direct-to-manufacturer pharmacy programs, and MMCAP's multi-state RFP for generic pharmaceuticals and OTC products — address pharmaceutical supply, distribution, and benefit management but do not isolate apomorphine as a line item or named product. State and local health agencies and cooperative purchasing organizations do source pharmaceuticals through these channels, with issuing bodies spanning county health departments (Seminole County, Florida), state HHS commissions (Texas), and multi-state procurement cooperatives (MMCAP, administered through the Minnesota Department of Administration). The work involves vendor qualification, wholesale network management, pricing negotiation, and compliance with FDA, cGMP, and Drug Supply Chain Security Act requirements.

Recent activity concentrates in Texas, Minnesota, and Florida. The Seminole County IFB (solicitation IFB60459723LAS, due Jul 26, 2023) sought naloxone and drug deactivation systems with quarterly deliveries and a two-year initial contract term. The MMCAP RFP (solicitation S1070000015802, due Mar 26, 2026) established multi-state contracts for generic pharmaceuticals with an effective date of Jul 1, 2026, requiring vendors to supply through three authorized wholesalers and accept a 3 percent administrative fee. The Texas HHS RFI (HHS0017013, posted Apr 3, 2026) gathered market intelligence on direct-to-manufacturer prescription programs before formal solicitation. None of these opportunities explicitly names apomorphine, suggesting the code may be misaligned with actual state and local purchasing in this product family or that apomorphine sourcing flows through broader pharmaceutical contracts rather than standalone procurement.